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Abstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson’s
disease. LRRK2 is highly expressed in immune cells and recent work points towards a link between LRRK2 and innate
immunity. Here we demonstrate that stimulation of the Toll-Like Receptor (TLR) pathway by MyD88-dependent agonists in
bone marrow-derived macrophages (BMDMs) or RAW264.7 macrophages induces marked phosphorylation of LRRK2 at
Ser910 and Ser935, the phosphorylation sites that regulate the binding of 14-3-3 to LRRK2. Phosphorylation of these
residues is prevented by knock-out of MyD88 in BMDMs, but not the alternative TLR adaptor protein TRIF. Utilising both
pharmacological inhibitors, including a new TAK1 inhibitor, NG25, and genetic models, we provide evidence that both the
canonical (IKKa and IKKb) and IKK-related (IKKe and TBK1) kinases mediate TLR agonist induced phosphorylation of LRRK2 in
vivo. Moreover, all four IKK members directly phosphorylate LRRK2 at Ser910 and Ser935 in vitro. Consistent with previous
work describing Ser910 and Ser935 as pharmacodynamic biomarkers of LRRK2 activity, we find that the TLR independent
basal phosphorylation of LRRK2 at Ser910 and Ser935 is abolished following treatment of macrophages with LRRK2 kinase
inhibitors. However, the increased phosphorylation of Ser910 and Ser935 induced by activation of the MyD88 pathway is
insensitive to LRRK2 kinase inhibitors. Finally, employing LRRK2-deficient BMDMs, we present data indicating that LRRK2
does not play a major role in regulating the secretion of inflammatory cytokines induced by activation of the MyD88
pathway. Our findings provide the first direct link between LRRK2 and the IKKs that mediate many immune responses.
Further work is required to uncover the physiological roles that phosphorylation of LRRK2 by IKKs play in controlling
macrophage biology and to determine how phosphorylation of LRRK2 by IKKs impacts upon the use of Ser910 and Ser935
as pharmacodynamic biomarkers.
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Introduction
Mutations in the gene encoding the protein kinase LRRK2
(leucine rich repeat kinase 2) cause autosomal dominant
Parkinson’s disease [1,2]. LRRK2 is a large multi-domain protein
kinase (2527 residues), consisting of leucine-rich repeats (residues
983–1320), a GTPase domain (residues 1335–1504), a COR [C-
terminal of Roc (Ras in complex proteins)] domain (residues
1517–1843), a serine/threonine protein kinase domain (residues
1875–2132) and a WD40 repeat (residues 2101–2517) [3,4]. Over
40 mutations in LRRK2 have been reported thus far which mainly
comprise amino acid substitutions [5]. The most common
mutation replaces glycine 2019 with a serine within the
magnesium-binding DYG motif (DFG motif in most other kinases)
of the kinase domain, thereby increasing LRRK2 activity 3-fold
[6,7]. This indicates that inhibitors of LRRK2 activity might be of
therapeutic benefit for the treatment of Parkinson’s disease. Little
is known about the physiological role of LRRK2 and to date no
properly validated substrates have been identified.
Recent work has revealed that LRRK2 interacts with 14-3-3
phospho-binding adaptor isoforms [8]. Phosphorylation of Ser910
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39132and Ser935 located prior to the leucine rich repeat domain
mediates binding of 14-3-3 isoforms to LRRK2 [8]. This binding
may be linked to Parkinson’s disease as phosphorylation of Ser910
and Ser935 and 14-3-3 binding is inhibited by five of the six
validated LRRK2 pathogenic mutations (R1441C, R1441G,
R1441H, Y1699C and I2020T) [8,9]. Intriguingly, treatment of
cell and animal models with structurally unrelated LRRK2 kinase
inhibitors also results in dephosphorylation of Ser910 and Ser935,
again accompanied by loss of 14-3-3 binding [10,11]. Recent work
has also revealed that LRRK2 inhibitors induce the dephosphor-
ylation of two other nearby residues that do not control 14-3-3
binding (Ser955 and Ser973) [12]. The kinase(s) and phosphatas-
e(s) that act on Ser910, Ser935, Ser955 and Ser973 are unknown,
but the evidence suggests that these residues are not phosphor-
ylated by LRRK2 itself [10].
Recent studies have demonstrated that LRRK2 is highly
expressed in immune cells, in particular, macrophages and B-
lymphocytes [13–15]. Furthermore the expression of LRRK2 is
reportedly increased in macrophages stimulated with interferon
gamma (IFNc)[13]. Another recent study has also suggested that
LRRK2 can modulate inflammatory cytokine secretion by
promoting cytoplasmic localisation of the Nuclear Factor of
Activated T-cells (NFAT) transcription factor, through a mecha-
nism that does not involve regulation of NFAT phosphorylation
[16].
Innate immune signaling can be triggered by activation of Toll-
like receptors (TLRs). These receptors consist of a family of
membrane proteins that sense pathogen-associated molecular
patterns [17,18]. TLR’s 1,2,5,6,7,8 and 9 signal through the
adaptor protein Myeloid Differentiation primary response gene-88
(MyD88) [19,20]. Stimulation of the MyD88 dependent pathway
results in the TNF receptor-associated factor 6 (TRAF6)-depen-
dent activation of the Transforming Growth Factor b–activated
kinase 1 (TAK1), which subsequently phosphorylates and activates
the ‘‘canonical’’ IkB kinases (termed IKKa and IKKb) to induce
transcription of Nuclear Factor-KappaB (NFkB) dependent genes
such as Interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha
(TNFa) [21]. Activation of the MyD88 pathway also results in
activation of the ‘‘non-canonical’’ IKK related kinases termed
TANK-binding kinase 1 (TBK1) and IKKe, which act to limit the
activation of the canonical IKKs [22,23]. TLR3 signals through
an alternative adaptor protein termed TIR-domain-containing
adapter-inducing Interferon-b (TRIF) [24]. This leads to the
activation of TBK1 and IKKe, which phosphorylate Interferon
Regulatory Factor-3 (IRF3) leading to induction of interferon-b
(IFNb) [17]. TLR4, which is activated by lipopolysaccharide
(LPS), is unique as it signals through both the MyD88 and TRIF
pathways [25]. Interestingly, although both the TRIF and MyD88
signalling pathways lead to activation of IKKe/TBK1, only
activation of the TRIF pathway is capable of inducing the
phosphorylation of IRF3 illustrating that biological consequences
of TBK1/IKKe activation depends on whether these enzymes are
activated by the MyD88 or TRIF pathways [23].
In this study we have raised highly sensitive rabbit monoclonal
antibodies that enable detection of the LRRK2 protein and its
phosphorylation at Ser935 by immunoblot analysis of cell extracts
of primary bone marrow-derived macrophages (BMDMs). We
utilised these antibodies to determine whether LRRK2 protein
expression or phosphorylation were altered in macrophages
treated with a number of agonists of immune signalling pathways.
Strikingly, we find that activation of the MyD88-dependent
pathway by TLR agonists induces marked phosphorylation of
LRRK2 at Ser935. We present biochemical, pharmacological as
well as genetic evidence that TBK1 and IKKe, as well as IKKa
and IKKb, mediate phosphorylation of Ser935 as well as Ser910
and Ser955 following activation of the MyD88-dependent TLR
pathway. The present study identifies LRRK2 as a novel
physiological substrate of IKKs and provides further intriguing
evidence supporting the view that LRRK2 may play a role in
immune signaling.
Methods
Reagents and General Methods
Toll receptor agonists were purchased from Invivogen. Signal
transduction inhibitors of TBK1/IKKe (MRT67307) [22], TAK1
(5Z-7-oxozeaenol) [26], IKKb (BI605906) [22] and LRRK2
(LRRK2-IN1 [11] and CZC25146 [27]) were provided by the
Division of Signal Transduction Therapy (DSTT), University of
Dundee, Scotland. A structurally unrelated TAK1 inhibitor,
termed NG25, was provided by Dr Nathanael Gray (see Method
S1 for the chemical synthesis of NG25). Tissue culture reagents
were from Life Technologies. Restriction digests, DNA ligations
and other recombinant DNA procedures were performed using
standard protocols. DNA mutagenesis was performed using the
Quickchange site directed mutagenesis kit (Stratagene). DNA
constructs used for transfection were purified from DH5a E.Coli
using Qiagen plasmid maxi-prep kits. All DNA constructs were
verified by sequencing performed by the sequencing service,
School of Life Sciences, University of Dundee. The following
substrates were generated by the DSTT by expression in BL21
E.Coli with an N-terminal GST tag (IkBa 2-54, LRRK2 882-1300,
IRF3 1-427 or maltose binding protein (MBP) tag (MKK6 2-334)
and purified using glutathione Sepharose or amylose resin
respectively. The kinases IKKe (1-716) and TAK1 (1-103)/
TAB1 (437-504) fusion were expressed in baculovirus with N-
terminal 66His tags and purified using Ni
2+-NTA agarose.
Antibodies
Antigens used to generate total LRRK2, LRRK2 phosphory-
lated at Ser910 and LRRK2 phosphorylated at Ser935 were the
same as used to generate the sheep polyclonal antibodies that have
been described previously [28] [8]. Rabbit monoclonal antibodies
were generated in conjunction with Epitomics. 211 clones and
subclones were screened by immunoblot using both recombinant
and endogenous LRRK2 to select the most sensitive. The optimal
clones were expanded for the production of purified antibody by
Epitomics. These antibodies are now distributed by the Michael J
Fox Foundation and can be purchased from Epitomics (Total
LRRK2[100-500] antibody catalogue number 5097-1; Phospho
Ser935 LRRK2 catalogue number 5099-1 and Phospho Ser910
antibody that detects only human but not mouse LRRK2
catalogue number is 5098-1. For immunoblot of mouse LRRK2,
a Phospho Ser910 sheep polyclonal antibody was used. All other
antibodies employed in this study were purchased from Cell
Signaling Technology.
Animals
Mice were maintained in accordance with UK and EU
regulations, and work was covered by an appropriate home office
license (60/3811) which was subject to review by the University of
Dundee Ethical Review Committee. LRRK2 knock-out mice were
generated and provided by Dr Huaibin Cai, Transgenics Section,
NIH, USA and have been described previously [29]. MyD88 [30]
and TRIF [24] null mice were generated and provided by Dr
Shizuo Akira, Department of Host Defense, Osaka University,
Japan. Bone marrow from IKKa double Ser176A and Ser180A
knock-in mice [31] was generously provided by Dr Toby
IKK’s Phosphorylate LRRK2
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Cell Culture, Treatments and Lysis
L929 cells were maintained in RPMI +10% (v/v) heat
inactivated FBS, 2 mM L-glutamine and 16 penicillin/strepto-
mycin. To generate L929 conditioned media, cells were seeded at
2610
5 cells per ml and media collected 7 days and 14 days after
seeding. Media was filtered through a 0.4 mM filter and stored at
280uC. 50 ml of Day 7 and 50 ml of Day 14 L929 conditioned
media was added to 400 ml RPMI containing 10% FBS to create
a base media for differentiating bone marrow derived macro-
phages [32]. Bone marrow precursor cells were extracted from
mouse femurs as described previously [22]. Briefly, femurs were
extracted under sterile conditions and bone marrow flushed with
PBS. Cells were washed with PBS and resuspended in L929
conditioned media for plating onto non-tissue culture treated petri
dishes. Half of the media was changed after 4 days. After 7 days
adherent macrophages were scraped from the petri dishes with
versene and then plated into tissue culture grade plastic 12 well, 6
well or 10 cm dishes and left for 24 h to re-attach before
experiments. Macrophage cultures were routinely .95% pure as
identified by flow cytometry analysis of the macrophage surface
marker F4/80. RAW264.7 cells were grown in DMEM containing
10% (v/v) heat inactivated FBS and 16 penicilin/streptomycin.
HEK293 cells were grown in DMEM containing 10% (v/v) FBS
and 16 penicillin/streptomycin. HEK293 cells were transfected
using the PEI method. TLR agonists were dissolved in LAL water
(Invivogen) and inhibitors dissolved in sterile DMSO. An
equivalent volume of DMSO was added to control samples where
appropriate. Following treatment, cells were lysed in buffer
containing 50 mM Tris.HCL pH 7.5, 1 mM EGTA, 1 mM
EDTA, 1 mM sodium orthovanadate, 10 mM b-glycerophos-
phate, 50 mM NAF, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 0.1% (v/v) 2-mercaptoethanol and 1% (v/v) Triton X-
100. Lysates were centrifuged at 12000 rpm for 20 min and
supernatants retained for protein assay (Coomassie protein assay
reagent, Thermo Scientific) and immunoblot.
Immunoblot Analysis
Cell lysates (8–20 mg) were resolved by SDS-PAGE using either
8%, 10% or Novex 4–12% gradient gels (Invitrogen) and
transferred to nitrocellulose membranes in the presence of 15%
(v/v) methanol. Membranes were blocked with 5% (w/v) skimmed
milk powder in TBST (Tris-buffered saline with Tween 20) buffer
(50 mM Tris.HCl pH 7.5, 0.15 M NaCl and 0.1%(v/v) Tween
20). Rabbit monoclonal LRRK2 antibodies were used at a
concentration of 100 ng/ml diluted in TBST with 5% (w/v)
bovine serum albumin (BSA). Cell Signaling Technology antibod-
ies were used at a dilution of 1/1000 overnight in TBST with 5%
(w/v) BSA. Anti-rabbit HRP (horseradish peroxidase) secondary
antibodies (Sigma) were used to detect immune complexes using
enhanced chemiluminescence reagent. 14-3-3 overlay far western
analysis was performed as described previously [8].
LRRK2 Peptide Kinase Assays
Kinase assays were performed using endogenous LRRK2
immunoprecipitated from 3 mg RAW264.7 cell lysate. Assays
were set up in a volume of 50 ml containing 50 mM Tris/HCl,
pH 7.5, 0.1 mM EGTA, 1 mM DTT, 10 mM MgCl2 0.1 mM
[c-
32P]ATP (300 cpm/pmol) and 20 mM Nictide peptide sub-
strate. Reactions were terminated after 20 min at 30uCb y
applying 40 ml of the reaction mixture to P81 phosphocellulose
paper and immersion in 50 mM phosphoric acid. After washing,
reaction products were quantified by Cerenkov counting. Kinase
activity is reported as pmol of ATP incorporated into Nictide per
minute per mg of lystate immunoprecipitated from as previously
described [28].
SILAC Phosphoproteomics
RAW264.7 cells were labelled using the Stable Isotope
Labelling of Amino Acids in Cell Culture (SILAC) method. Cells
were treated with 2 mM MRT67307 or vehicle control for 1 h and
subsequently, left unstimulated or stimulated with 1 mg/ml
Pam3CSK4 for 30 min. The cells were lysed, proteins were
reduced, alkylated and digested with trypsin. Phosphopeptides
were enriched by sequential hydrophilic (HILIC) chromatography
followed by Fe
3+-IMAC chromatography [33]. Phosphopeptides
were measured by LC-MS/MS on Thermo Fisher Scientific LTQ
Orbitrap Velos instrument set to perform top-15 data-dependent
CID analysis in the 350–1600 m/z range using a resolution of
60000 for the precursor scan and a minimal intensity for
sequencing of 10000 counts. Monoisotopic precursor selection
was used and +1 as well as unassigned charge states were excluded
from sequencing. Dynamic exclusion was set to a repeat count of 2
within 30 sec, with exclusion duration of 90 sec and an exclusion
mass width of 10 ppm. The data was analysed using MaxQuant
[34].
qRT-PCR
RNA was extracted using Rneasy micro kits (Qiagen) with
QIAshredders (Qiagen) used for cell disruption. RNA was reverse
transcribed using the IQscript system (Biorad). qRT-PCR was
performed on a Biorad CFX realtime system using 20 ml reactions
in duplicate. Ssofast Evergreen Supermix (Biorad) was used to
measure amplification of diluted cDNA, which was then
normalized to the housekeeping gene GAPDH. Fold difference
in gene expression was calculated using the comparative Ct
method (2
2ddct). PCR efficiencies were similar between primer sets
and the expression of the housekeeping gene did not change with
TLR agonist treatment. Primer sets for inflammatory cytokine
genes are listed in Table S4.
Cytokine Measurements
For the measurement of inflammatory cytokine release in
culture media, BMDMs were plated at a density of 1610
6 in 6 well
tissue culture plates. Media was collected 8 h post stimulation and
stored at 280uC until analysis. TNFa, IL-6, IL-12(p40),
RANTES, IL-10, IL-1b, MCP-1 and KC were measured using
a bioplex-pro cytokine assay and Luminex technology (Biorad)
according to the manufacturers instructions.
In vitro Phosphorylation Reactions
In vitro phosphorylation reactions were performed in a
volume of 50 ml containing 50 mM Tris.HCl, pH 7.5, 0.1 mM
EGTA, 1 mM DTT, 10 mM MgCl2, 0.1 mM [c-
32P]ATP
(300 cpm/pmol), 2 mM substrate and kinase. For baculovirus
expressed and purified kinase 0.2 mg of recombinant kinase was
used per reaction. For kinases expressed in HEK293 cells, 5 ml
of HA-agarose was used to immunoprecipitate the overex-
pressed kinase from 1–5 mg of lysate. Beads were washed five
times with lysis buffer containing 0.5 M NaCl and once in
kinase assay buffer before being utilised for in vitro phosphor-
ylation reactions. Assays were undertaken at 30uC for 30 min
and terminated by addition of 46 lithium dodecyl sulfate (LDS)
sample buffer (Invitrogen).
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Generation of Rabbit Monoclonal Antibodies
We generated rabbit monoclonal antibodies that efficiently
recognize endogenous LRRK2 protein and LRRK2 phosphory-
lated at Ser935 in cell extracts. These antibodies recognise
LRRK2 as the major band on immunoblot analysis and their
specificity is confirmed by loss of signal in LRRK2 knock-out
fibroblasts (Fig 1 A & Fig 1B). Moreover, mutation of Ser935 to
Ala or treatment with the LRRK2-IN1 inhibitor to induce
dephosphorylation of LRRK2, abolished recognition by the
LRRK2 Ser935 phospho-antibody (Fig 1B).
TLR Activation Stimulates LRRK2 Ser935 Phosphorylation
It has recently been described that the JAK-STAT pathway
agonist IFNc can induce the expression of LRRK2 [13]. We
therefore utilised our newly generated antibodies to determine if
other agonists of immune signalling pathways altered LRRK2
expression or phosphorylation in macrophages. We first examined
levels of LRRK2 protein as well as Ser935 phosphorylation
following stimulation of BMDMs with LPS, an agonist for TLR4,
over a 24 h period (Fig 2A & 2B). Although no marked changes in
LRRK2 protein expression were observed, LPS induced a striking
phosphorylation of Ser935 within 30 min (Fig 2A). This was
sustained for up to 6 h and gradually decreased to basal levels by
12 h (Fig 2B). In parallel the phosphorylation of p105 at Ser933
mediated by IKKa/IKKb and phosphorylation of the JNK and
p38 MAP kinases increased within 10 min in response to LPS and
declined subsequently, as expected (Fig 2A and 2B).
We next treated BMDMs with the bacterial lipopeptide Pam3-
Cys-Ser-Lys4 (Pam3CSK4), an agonist that stimulates signalling
through the MyD88 pathway through the heterodimeric TLR1/
TLR2 complex. This similarly induced phosphorylation of
LRRK2 at Ser935 within 30 min, again slower than the
phosphorylation of p105, JNK and p38 (Fig 2C). Phosphorylation
of LRRK2 at Ser935 induced by Pam3CSK4 was sustained for
24 h while the peak phosphorylation of p105, JNK and p38 was
more transient (Fig 2D).
We next stimulated BMDMs with a panel of TLR agonists
revealingthatallagoniststestedthatsignalviatheMYD88pathway
namelyTLR2(HeatKilledListeriamonocytogenesHKLM),TLR5
(Flagellin), TLR6 (Synthetic diacylated lipoprotein, FSL1), TLR7
(Imidazoquinoline compound-97, CLO97) and TLR9 (synthetic
oligodeoxynucleotide containing unmethylated CpG motifs termed
ODN1826)inducedphosphorylationofLRRK2atSer935similarly
toLPSandPam3CSK4(Fig2E).Incontrast,TLR3agonists(highand
low molecular weight Polyinosine-polycytidylic acid, PolyI:C) that
signal through the TRIF pathway, failed to induce Ser935
phosphorylation. We also tested TLR3 agonists over a 24 h time
periodandobservednosignificantphosphorylationofSer935despite
observing phosphorylation of p105, p38, JNK and IRF3 indicating
thatactivationoftheTRIFpathwayhadoccurred(Fig2F&2G).We
also investigated the effect of TLR agonists on LRRK2 phosphor-
ylation in RAW264.7 macrophage cells. In this cell line LRRK2
Ser935 phosphorylation was also increased by Pam3CSK4, LPS,
FSL1 and ODN1826 (Fig S1). As LRRK2 is highly abundant in
RAW264.7 cells, we were also able to detect an increase in the
phosphorylation of Ser910(FigS1).
We also stimulated BMDMs with agonists of other immune
signalingpathwaysincludingTNFa(Fig3A),theNucleotide-binding
oligomerisation domain-containing protein 2 (NOD2) agonist
muramyl dipeptide (MDP) and the NOD1 agonist ie-DAP (data
notshown).Weobservedthatthesefailedtoinducephosphorylation
of LRRK2 at Ser935 over a 2h time course, despite inducing
phosphorylationofp105andp38(TNFa&NOD2)andJNK(TNFa).
In contrast, the yeast cell wall glucan component zymosan that
activates both TLR2 and the C-type lectin receptor dectin-1,
promoted Ser935 phosphorylation of LRRK2 (Fig 3B). The time
course of Ser935 phosphorylation following zymosan treatment
followed that of LPS with phosphorylation markedly increased by
30 min(Fig3B)andremainingelevatedfor8h(Fig3C).Theeffectof
zymosanininducingSer935phosphorylationislikelytobemediated
via the TLR2 pathway however, as the dectin-1 specific agonist
curdlan failed to induce phosphorylation of Ser935 over the same
timecourse (Fig3D and 3E).
LRRK2 Phosphorylation is MyD88-dependent
To verify that the MyD88 pathway was critical for enabling
LRRK2 to become phosphorylated at Ser935, we generated
BMDMs from littermate wild type and MyD88 knock-out mice
and observed that the TLR agonists Pam3CSK4 (TLR1/TLR2),
FSL1 (TLR6) and ODN1826 (TLR9) failed to stimulate phosphor-
ylation of Ser935 in MyD88 knock-outs (Fig 4A). Although LPS
Figure 1. Generation of rabbit monoclonal LRRK2 antibodies.
(A) Purified rabbit monoclonal antibody raised against residues 100–
500 of human LRRK2 was used to immunoblot 5 mg HEK293 cell lysate
containing overexpressed GFP-LRRK2 variants, 30 mg LRRK2 wild type
and knock-out mouse embryonic fibroblast (MEF) lysate and 30 mg
human lymphoblastoid cell lysate. Lymphoblast and MEF cells were
treated plus or minus 1 mM LRRK2-IN1 for 2 h. A longer exposure was
required for the MEF LRRK2 signal. (B)A si nA except a rabbit
monoclonal antibody to LRRK2 phosphorylated at Ser935 was used.
doi:10.1371/journal.pone.0039132.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39132Figure 2. TLR agonists increase LRRK2 phosphorylation at Ser935. (A&B ). Primary bone marrow derived macrophages were treated with
100 ng/ml LPS for the indicated time points before cell lysis and immunoblot with indicated antibodies. (C&D ) Primary bone marrow derived
macrophages were treated with 1 mg/ml Pam3CSK4 for the indicated time points before cell lysis and immunoblot with indicated antibodies. (E)
Primary bone marrow derived macrophages were treated with the following TLR agonists for 1 h. 1 mg/ml Pam3CSK4,1 0
8 cells HKLM, 10 mg/ml LMW
and HMW Poly(I:C), 100 ng/ml LPS, 10 mg/ml Flagellin, 1 mg/ml FSL1, 1 mM CLO97 and 2.5 mM ODN1826. (F&G ) Primary bone marrow derived
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phages,emphasisedbyphosphorylationofp38andJNK,LPSfailed
toinduceSer935phosphorylation(Fig4A).Wealsoobservedthatthe
basal phosphorylation of Ser935 was similar in non-stimulated wild
typeandMyD88knock-outmacrophagesindicatingthataMyD88-
independent pathway controls basal phosphorylation (Fig 4A). We
alsofoundinTRIFknock-outBMDMsthatSer935phosphorylation
isincreasedtothesameextentasinwild-typemacrophagesfollowing
LPS stimulation, further suggesting that the TRIF pathway is not
regulating Ser935phosphorylation (Fig 4B).
LRRK2 Kinase Activity is not Required for TLR Mediated
Ser935 Phosphorylation
As mentioned in the introduction treatment of cells or mice
with LRRK2 kinase inhibitors induces dephosphorylation of
LRRK2 at Ser910 and Ser935 [10,11]. We therefore explored
the effect that the LRRK2 kinase inhibitors, LRRK2-IN1 and
CZC25146, had on basal as well as MyD88 pathway-induced
Ser935 phosphorylation observed in BMDMs. Consistent with
previous observations, treatment of non-stimulated BMDMs
with LRRK kinase inhibitors, reduced the basal level of
LRRK2 Ser935 phosphorylation to barely detectable levels
(Fig 5A). In contrast however, LRRK2-IN1 had no effect on
Ser935 phosphorylation induced by LPS or Pam3CSK4 (Fig 5B).
Likewise CZC25146 failed to block the LPS or Pam3CSK4
phosphorylation of LRRK2 Ser935 in BMDMs at a number of
concentrations tested (Fig 5C). We also investigated the effect of
LRRK2-IN1 in RAW264.7 cells. Consistent with the results
from BMDMs, LRRK2-IN1 reduced the basal phosphorylation
of Ser935, as well as Ser910, but LRRK2-IN1 failed to suppress
macrophages were treated with 10 mg/ml Poly(I:C) for the indicated time points before cell lysis and immunoblot with indicated antibodies. All
immunoblots are representative of at least two independent experiments.
doi:10.1371/journal.pone.0039132.g002
Figure 3. Non-TLR immune agonists fail to increase LRRK2 phosphorylation. (A) Primary bone marrow derived macrophages were treated
with 100 ng/ml TNFa for the indicated time points before cell lysis and immunoblot with the indicated antibodies. (B&C )A si nA except 200 mg/ml
zymosan was used. (D and E)a si nA except that 100 mg/ml curdlan was used. Immunoblots are representative of at least two independent
experiments.
doi:10.1371/journal.pone.0039132.g003
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indicates that, unlike basal Ser910 and Ser935 phosphorylation,
the phosphorylation induced by LPS and Pam3CSK4 is not
regulated by LRRK2 kinase activity.
To examine the direct effect of LPS and Pam3CSK4 on LRRK2
kinase activity we employed the murine macrophage cell line
RAW264.7, as we were unable to culture sufficient BMDMs to
assess LRRK2 catalytic activity robustly. Increased phosphoryla-
tion of Ser935 following treatment of RAW264.7 cells with LPS or
Pam3CSK4 resulted in increased binding of 14-3-3 in a far
Western assay, however, the kinase activity of immunoprecipitated
LRRK2 did not differ significantly (Fig 5D). This is consistent with
our previous work that indicated that phosphorylation of Ser910/
Ser935 and 14-3-3 binding had no impact on LRRK2 protein
kinase activity [8].
TBK1 and IKKe Contribute to MYD88-pathway Mediated
Phosphorylation of LRRK2
We next investigated how inhibition of TBK1 and IKKe
impacted on LRRK2 phosphorylation, using an inhibitor
termed MRT67307 [22]. We employed a quantitative stable
isotope labelling with amino acids in cell culture (SILAC) mass
spectroscopy approach to study LRRK2 phosphorylation in
RAW264.7 macrophages that were stimulated in the presence
or absence of Pam3CSK4 and MRT67307 (Fig. 6A). After
enrichment of the phosphopeptides using sequential hydrophilic
interaction chromatography and immobilized metal ion affinity
chromatography, we were able to identify three LRRK2 derived
phosphopeptides encompassing Ser910, Ser935 and Ser955. In
addition we also identified a peptide encompassing Ser177 of
optineurin a known TBK1/IKKe substrate [35] (Fig 6B, 6C,
6D, 6E, 6F). Pam3CSK4 significantly enhanced phosphorylation
of Ser935, which was partially inhibited by MRT67307 (Fig 6B).
Interestingly, Pam3CSK4 also induced phosphorylation of
Ser910 and Ser955 as well as optineurin at Ser177, and the
phosphorylation of all these residues was similarly inhibited by
MRT67307 (Fig 6C, 6D, 6E, 6F). This suggests that TBK1/
IKKe may also regulate the phosphorylation of Ser910 and
Ser955 in addition to Ser935.
Employing a phosphospecific Ser935 antibody we also con-
firmed in BMDMs that following LPS stimulation, under
conditions in which MRT67307 ablated phosphorylation of the
TBK1/IKKe substrate IRF3 at Ser396, it also partially reduced
the phosphorylation of LRRK2 at Ser935 (Fig 6G). The inhibitory
effect of MRT67307 was most pronounced at the 20–30 min time
points of LPS treatment (Fig 6G).
IKKa and IKKb Contribute to MyD88-pathway Mediated
Phosphorylation of LRRK2
The finding that MRT67307 only partially inhibited LPS or
Pam3CSK4 induced phosphorylation of Ser935 at earlier time
points, suggested that other MyD88-activated protein kinases were
involved in phosphorylating Ser935. To investigate whether the
related IKKa and IKKb could contribute to phosphorylation of
Ser935, we treated cells with MRT67307 (to inhibit TBK1/IKKe)
in combination with either of two structurally unrelated kinase
inhibitors that inhibit the TAK1 protein kinase termed NG25 or
5Z-7-oxozeaenol and therefore also inhibit activation of IKKa and
IKKb. The structure of NG25 and its method of synthesis is
shown in method S1. NG25 inhibited TAK1 in vitro with an IC50
of 4 nM and has previously been shown to inhibit TAK1 in cells
[36]. The selectivity of NG25 against numerous kinases was
measured by ActivX KiNativ profiling [37] (Table S1), Ambit
profiling (Table S2) or radioactive filter binding assay performed at
the International Centre for Kinase Profiling (Table S3) showing
that NG25 is a relatively specific inhibitor for TAK1. When either
5Z-7-oxozeaenol or NG25 were used in combination with
MRT67307, LPS induced phosphorylation was completely
prevented (Fig 7A). In contrast, treatment of BMDMs with either
NG25 or 5Z-7-oxozeaenol in the absence of MRT67307 had no
significant effect on Ser935 phosphorylation following stimulation
with LPS, under conditions where these compounds inhibited
p105, JNK and p38 activation (Fig 7A).
We also used an IKKb inhibitor, BI605906 [22], in combina-
tion with MRT67307 and found that this did not reduce LPS
mediated phosphorylation of Ser935 any more than MRT67307
employed alone (Fig 7B), indicating that IKKa might be
responsible for residual phosphorylation. To test this we treated
BMDMs derived from knock-in mice expressing catalytically
inactive IKKa with MRT67307 (to inhibit IKKe and TBK1) and
BI605906 (to inhibit IKKb). This ablated phosphorylation of
Ser935 (Fig 7B), supporting the view that all four IKK’s contribute
to LRRK2 Ser935 phosphorylation in macrophages.
As mentioned above Zymosan also induces phosphorylation of
LRRK2 at Ser935, probably vial TLR2 but not the dectin-1
pathway (Fig 3D). Consistent with this treatment of BMDMs with
both the TAK1 5Z-7-oxozeaenol inhibitor and the TBK1/IKKe
inhibitor MRT67307 was required to block phosphorylation of
LRRK2 at Ser935 induced by Zymosan (Fig 7C).
Figure 4. TLR induced LRRK2 Ser935 phosphorylation is
MYD88-dependent. (A) Primary bone marrow derived macrophages
were generated from MYD88 knock-out mice and wild type littermate
controls. Macrophages were stimulated with either 1 mg/ml Pam3CSK4,
100 ng/ml LPS, 1 mg/ml FSL1 or 2.5 mM ODN1826 for 1 h. Cell lysates
were prepared and subjected to immunoblot with the indicated
antibodies. (B)A si nA except that macrophages were generated from
TRIF knock-out mice and wild type littermate controls. All immunoblots
are representative of at least two independent experiments.
doi:10.1371/journal.pone.0039132.g004
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and Ser935 in vitro
We next expressed wild type and kinase-inactive mutants of HA
epitopetaggedIKKa,IKKb,TBK1andIKKeinHEK293cellsand
tested whether these could phosphorylate Ser935 as well as Ser910
employing phosphospecific antibodies that recognisethese residues.
This revealed that all four wild type, but not similar levels of kinase-
inactive, IKK isoforms phosphorylated LRRK2 at Ser910 and
Ser935 in vitro. TBK1 and IKKe phosphorylated LRRK2 to a
markedly greater extent than IKKa and IKKb under conditions in
which all four IKK isoforms phosphorylated IkBa at Ser32 to a
similarextent(Fig7D).Wealsotestedwhetherbaculovirusexpressed
TAK1 was able to phosphorylate LRRK2 and found that although
TAK1 phosphorylated a known substrate MKK6, it failed to
phosphorylate LRRK2at Ser910or Ser935(Fig7E).
IKK-mediated Cytokine Signaling is not Impaired in
LRRK2 Deficient Macrophages
We next examined cytokine secretion (IL-6, keratinocyte
chemoattractant, RANTES, IL-1b, Monocyte chemoattractant
protein 1, IL-10, TNFa and IL-12 (p40)) in wild type or LRRK2
knock-out BMDMs at 0 h, 4 h, 8 h and 12 h following stimulation
Figure 5. Ser935 phosphorylation during TLR signaling does not require LRRK2 kinase activity. (A) Primary bone marrow derived
macrophages were treated with indicated concentrations of LRRK2-IN1 or CZC25146 or DMSO as control for 1 h. Cell lysates were prepared and
subjected to immunoblot with the indicated antibodies. (B) Primary bone marrow derived macrophages were pre-treated with indicated
concentrations of LRRK2-IN1 or CZC25146 or DMSO as control for 1 h before stimulation with 100 ng/ml LPS for 1h. Cell lysates were prepared and
subjected to immunoblot with the indicated antibodies. (C)A si nB except 1 mg/ml Pam3CSK4 was used. (D) RAW264.7 cells were treated with
100 ng/ml LPS or 1 mg/ml Pam3CSK4 for 1 h before cell lysis. Endogenous LRRK2 was immunoprecipitated from 3 mg RAW264.7 cell lysate with 3 mg
rabbit monoclonal LRRK2 100–500 antibody. Kinase activity was measured using 20 mM Nictide with n=4 in duplicate. Kinase activity is reported as
pmol of ATP incorporated into Nictide per minute per mg of lystate immunoprecipitated from. A parallel set of immunoprecipitations was used to
measure 14-3-3 binding by overlay assay. All results are representative of at least two independent experiments.
doi:10.1371/journal.pone.0039132.g005
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mRNA expression of cytokines at 0 h, 4 h, 8 h and 12 h post
stimulation with LPS (Table 3) or Pam3CSK4 (Table 4). As
expected LPS and Pam3CSK4 induced profound increases in
cytokine secretion and cytokine mRNA expression, but no
consistent significant differences were observed between the wild
type and LRRK2 knock-out BMDMs (Tables 1, 2, 3, 4).
Additionally we found that there were no differences in the time
course of LPS-induced phosphorylation of TAK1, IKKa/IKKb,
p105, IkB, JNK, p38, TBK1 or IRF3 in wild type and LRRK2
knock-out BMDMs (Fig 8).
Discussion
In light of recent findings that LRRK2 is highly expressed in
immune cells and that the expression of LRRK2 can be further
modulated by IFNc [13], we utilised novel and highly sensitive
LRRK2 antibodies to investigate the expression and phosphory-
lation of LRRK2 in response to agonists of innate immune
signalling pathways. The key finding of this study is that all
MyD88 agonists tested trigger marked phosphorylation of LRRK2
at the 14-3-3 binding sites Ser910 and Ser935. Monitoring
phosphorylation of LRRK2 in RAW264.7 macrophages (Fig 6),
Figure 6. TBK1 and IKKe regulate LRRK2 Ser935 phosphorylation following TLR activation. A) Schematic of SILAC experiment. B-E)
Extracted Ion Current for phosphopeptides encompassing Ser935 (B), Ser910 (C) and Ser955 (D) of LRRK2 and Ser177 of optineurin (E). The results for
unstimulated RAW264.7 macrophages are presented in blue, results for RAW264.7 macrophages stimulated for 60 min with Pam3CSK4 (1 mg/ml) are
in green and the results from RAW264.7 macrophages pre-treated with 2 mM MRT67307 prior to stimulation with Pam3CSK4 (1 mg/ml) for 60 min are
depicted in red. (F) Table summarizing the results of the phosphopeptides from LRRK2 identified in the phosphoproteomics screen. G) Primary bone
marrow derived macrophages were pre-treated with 2 mM MRT67307 or DMSO control for 1 h before stimulation with 100 ng/ml LPS for the
indicated time points. Immunoblots are representative of at least two independent experiments.
doi:10.1371/journal.pone.0039132.g006
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macrophages were treated with either DMSO, 1 mM 5z-7-Oxozeanol (TAK1 inhibitor), 2 mM NG25 (TAK1 inhibitor), 2 mM MRT67307 (TBK1/IKKe
inhibitor) or 10 mM B1605906 (IKKb inhibitor) alone or in the indicated combinations for 1 h before stimulation with 100 ng/ml LPS for 1 h. Cell
lysates were subjected to immunoblot analysis with the indicated antibodies. (B) Bone marrow derived macrophages were generated from
kinase inactive IKKa double Ser176A and Ser180A knock-in mice or littermate wild type controls. Macrophages were treated with either DMSO,
2 mM MRT67307 (TBK1/IKKe inhibitor) or 10 mM B1605906 (IKKb inhibitor) as indicated for 1 h before stimulation with 100 ng/ml LPS for 1 h.
Cell lysates were subjected to immunoblot analysis with the indicated antibodies. (C)A si nA except that BMDMs were treated with DMSO,
1 mM 5z-7-Oxozeanol (TAK1 inhibitor), 2 mM MRT67307 (TBK1/IKKe inhibitor) alone or in combination for 1 h before stimulation with 1 mg/ml
Pam3CSK4 or 200 mg/ml zymosan. (D) Ha tagged wild type and kinase inactive variants of IKKa IKKb IKKe and TBK1 were expressed by
IKK’s Phosphorylate LRRK2
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39132we find evidence that phosphorylation of Ser955 is enhanced by
Pam3CSK4 and inhibited with the TBK1/IKKe inhibitor
MRT67307 similarly to Ser910 and Ser935. A recent report
suggests treatment of cells with LRRK2 induces dephosphoryla-
tion of Ser910, and Ser935 as well as Ser955 and Ser973 [12,38]
and the amino acid sequence surrounding these residues are
similar. Taken together with the data presented in this paper this
suggests that these residues are similarly regulated. Further work
will be required to determine whether the phosphorylation of S955
and S973 in vivo is regulated by IKKs when state of the art
phospho-specific antibodies for these residues become readily
available.
Our data suggest that phosphorylation of Ser910 and Ser935 is
likely to be mediated directly by the canonical as well as non-
canonical IKK kinases. Not only do these enzymes directly
phosphorylate Ser935 as well as Ser910 in vitro, but combinations
of inhibitors that prevent activation of these enzymes also inhibited
LPS-stimulated phosphorylation of these sites in vivo. In vitro,
LRRK2 was phosphorylated to a greater extent by the IKK
related kinases (TBK1 and IKKe) rather than the canonical IKKs
(IKKa and IKKb). Also inhibition of TBK1 and IKKe using
MRT67307 resulted in a partial inhibition of Ser935 phosphor-
ylation whilst inhibition of the activation of IKKa and IKKb with
TAK1 inhibitors had no effect alone on LRRK2 phosphorylation.
The relative contribution of each IKK to phosphorylation of
Ser910, Ser935 and potentially S955 remains to be determined.
Our data does not rule out the possibility that other kinases that
we have not identified and that might be regulated by IKKs,
control phosphorylation of Ser910, Ser935 and Ser955. PKA has
been suggested as a kinase capable of phosphorylating LRRK2 at
Ser935 in vitro and by transfection in cell culture [9,39] however,
validation of PKA as an upstream kinase for LRRK2 remains to
be demonstrated at the endogenous level.
Recent work has uncovered other substrates that can be
phosphorylated by the four IKK isoforms. These include NEMO
and TANK [22] where inhibition of both the TBK1/IKKe and
IKKa/IKKb branches of the MyD88 pathway are required to
suppress phosphorylation. Optineurin is also phosphorylated by
the 4 IKK members, but in this case the canonical and non-
canonical IKKs phosphorylate different residues (IKKa/IKKb-
Ser513 and TBK1/IKKe-Ser177) preferentially [35]. In the case
of optineurin, Ser177 was phosphorylated when macrophages
were stimulated with Poly(I:C) a TLR3 agonist that signals via
TRIF, or the TLR1/2 agonist Pam3CSK4 [35] which signals via
MyD88. This differs from Ser935 of LRRK2, which is only
phosphorylated when TBK1/IKKe are activated by the MyD88
signalling pathway. In contrast, IRF3, is only phosphorylated at
Ser396 when TBK1/IKKe are activated via the TRIF-dependent
pathway [23,24]. These observations provide further evidence that
the substrates that TBK1/IKKe phosphorylate are determined by
the pathway that leads to their activation. This could be explained
if the MyD88 and TRIF pathways activate distinct pools of
TBK1/IKKe, which are targeted to specific subsets of substrates.
To our knowledge LRRK2 is the first substrate to be reported that
is phosphorylated by all four IKK family members in only a
MyD88-dependent manner.
That LRRK2 is phosphorylated during inflammatory signalling
is of interest as increasing evidence suggests that inflammation is
linked to the progression of neurodegeneration and Parkinson’s
disease [38,40,41]. Increased IL-6 and increased TNFa have been
found in the brains, CSF and serum of patients with PD [42–46].
In PD, increased inflammatory cytokine secretion is associated
with the activation of microglia, the resident macrophages of the
brain [47]. In rodent models, activation of microglia with either
central or peripheral LPS induces loss of dopaminergic substantia
nigra neurons [48–50]. Neuroinflammation is also observed in
other routinely used PD animal models including the 6-hydroxy-
dopamine and MPTP models [51,52]. In the 6-hydroxydopamine
model, inhibiting tumour necrosis factor signaling can attenuate
loss of dopaminergic neurons [53].
transfection into HEK293 cells then immunoprecipitated by Ha-agarose. Kinases were used to phosphorylate bacterially expressed substrates
GST-LRRK2 (882-1300), GST-IkBa (2-54) and GST-IRF3 (1-427) at 30uC for 30 min before reaction termination with sample buffer. 10% of the in
vitro phosphorylation reaction was used for immunoblot analysis with the indicated antibodies. E) Baculovirus expressed TAK1 and IKKe were
used to phosphorylate bacterially expressed substrates GST-LRRK2 (882-1300), GST-MKK6 (2-334) and GST-IRF3 (1-427) at 30uC for 30 min before
reaction termination with sample buffer. 10% of the in vitro phosphorylation reaction was used for immunoblot analysis with the indicated
antibodies or for autoradiograph.
doi:10.1371/journal.pone.0039132.g007
Table 1. Cytokine secretion in wild type and LRRK2 KO BMDM’s following LPS stimulation.
Analyte Time =0 Time =4 h Time =8 h Time =12 h
WT KO WT KO WT KO WT KO
IL-6 ND ND 209686 231626 15316110 12786199 21076127 15926210
KC ND ND 944664 6906165 1045654 7256136 12456162 9016114
RANTES 5.9561.28 4.0661.00 617675 587678 52036266 48876734 1404361653 1136261206
IL-1b ND ND ND ND 9.9062.27 9.3662.16 12.7462.31 16.8266.74
MCP1 ND ND 45246253 48416589 93366461 73776740 1099861875 1493762006
IL-10 5.4160.34 4.2860.79 99.2610.3 135.9630.2 479626 403676 346.8614.4 448.5684.3
TNFa ND ND 62206562 86416998 39346233 28516333 2122647 18316163
IL-12 (p40) ND ND 189616 186643 14556109 11926154 26886316 23476308
Bone marrow derived macrophages from LRRK2 knockout mice and wild type littermate controls were plated at a density of 1610
6 in 2 ml of tissue culture
media. Cells were treated with 100 ng/ml LPS 24 h after plating and media collected at the indicated time points. Cytokines were measured with an antibody
based multiplex assay and concentrations determined by standard curve. Data is presented as mean concentration in pg/ml 6 S.E.M. Experiments were performed
with n=4 in duplicate.
doi:10.1371/journal.pone.0039132.t001
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LRRK2 are significant risk factors in Crohn’s disease, an
inflammatory disease of the bowel [54–56]. Supporting a role of
LRRK2 in Crohn’s disease, LRRK2 knock-out macrophages
display increased production of the inflammatory cytokines IL-
12 and IL-6 when stimulated with the yeast cell wall glucan
component, zymosan, rendering these mice more susceptible to
inflammatory bowel disease in a mouse model [16]. Although
zymosan activates both TLR2 and dectin-1, evidence suggests
that regulation of NFAT by zymosan is mediated via dectin-1
[57]. Curdlan, a specific activator of dectin-1, that does not
activate TLR2, did not increase the phosphorylation of LRRK2
at Ser935 (Fig 3F). Consistent with the effects of zymosan-
stimulated phosphorylation of LRRK2 being mediated via a
TLR2-MYD88 pathway, we found that the ability of zymosan
to induce phosphorylation of Ser935 was prevented by
inhibition of both TBK1/IKKe with MRT67307 and TAK1
with 5Z-7-oxozeaenol (Fig 7C). If the effects of zymosan on
NFAT localisation are mediated through the dectin-1 pathway,
this would indicate that LRRK2 phosphorylation at serines 910
and 935 by the MyD88 pathway is not involved in controlling
NFAT. The finding that LRRK2 knock-out had no effect on
either Pam3CSK4 or LPS-induced inflammatory cytokine
expression and secretion also indicates that NFAT is unlikely
to be controlled directly by LRRK2 in the TLR signalling
network.
More work is required to uncover how phosphorylation of
LRRK2 by the IKK family kinases regulates function and impacts
on macrophage biology. It may be necessary to generate LRRK2
knock-in mice that cannot be phosphorylated by TBK1/IKK
isoforms to address this question. A number of recent studies have
implicated both TBK1 [58,59] and LRRK2 in controlling
autophagy [60–62]. We have undertaken some initial studies in
wild type and LRRK2 knock-out BMDMs stimulated with LPS or
starved of amino acids looking at various autophagic markers, such
as levels of LC3 lipidation and p62 levels. However, thus far we
have not observed any significant differences between wild type
and LRRK2 knock-out macrophages (FIV and Ian Ganley
unpublished).
A final aspect of this work relates to the use of phospho-specific
antibodies recognising phosphorylated Ser910 and Ser935 as
biomarkers for LRRK2 inhibitors. As dephosphorylation of
LRRK2 at Ser935 and Ser910 is being used to evaluate the
efficacy of LRRK2 inhibitors, the work described in this study
reveals some limitations to our previous hypothesis relating to
using dephosphorylation of these residues as pharmacodynamic
Table 2. Cytokine secretion in wild type and LRRK2 KO BMDM’s following PAM3CSK4 stimulation.
Analyte Time =0 Time =4 h Time =8 h Time =12 h
WT KO WT KO WT KO WT KO
IL-6 ND ND 18.666.1 19.167.8 19656337 17016363 647061755 847061688
KC ND ND 9476132 5286133 803361426 535061139 1723863799 1360865972
RANTES 5.9561.28 4.0661.00 45.3610.9 35.6611.2 8366213 7076123 30576864 24026267
IL-1b ND ND ND ND 7.5861.92 9.3662.16 25.065.69 21.565.92
MCP1 ND ND 164678 95.8625 329699 245683 19456276 9716282
IL-10 5.4160.34 4.2860.79 63.267.3 51.9612.0 158616 140625 172610 135627
TNFa ND ND 9956207 839656 30076271 22236395 24546170 22816181
IL-12 (p40) ND ND 17.260.57 16.162.09 188633 168627 663666 524642
Bone marrow derived macrophages from LRRK2 knockout mice and wild type littermate controls were plated at a density of 1610
6 in 2 ml of tissue culture media. Cells
were treated with 1 mg/ml Pam3CSK4 24 h after plating and media collected at the indicated time points. Cytokines were measured with an antibody based multiplex
assay and concentrations determined by standard curve. Data is presented as mean concentration in pg/ml 6 S.E.M. Experiments were performed with n=4 in
duplicate.
doi:10.1371/journal.pone.0039132.t002
Table 3. mRNA expression in wild type and LRRK2 KO BMDM’s following LPS stimulation.
Gene Time =0 Time =4h Time =8h Time =12h
WT KO WT KO WT KO WT KO
IL-6 1.060.12 1.160.09 802661068 1012862939 7476367988 7036566522 6945068032 7636766240
IL-1b 1.060.17 1.060.11 10636106 7806174 17106173 17506129 786664 843697
TNFa 1.060.04 1.360.08 5362.2 6365.1 3362.5 3065.3 1661.2 1360.84
IFNb 1.060.24 1.460.35 829562299 1005061291 22326297 28036335 6496165 932682
IL-12(p70) 1.060.11 1.160.71 86276958 71226727 29226228 29516240 1425658 19426144
IL-12 (p40) 1.060.57 1.160.29 2436163392 2518061050 1761061518 1267162077 72066645 98046660
Bone marrow derived macrophages from LRRK2 knockout mice and wild type littermate controls were plated at a density of 1610
6 in 2 ml of tissue culture media. Cells
were treated with 100 ng/ml LPS 24 h after plating and RNA collected at the indicated time points. Gene expression was normalized to GAPDH and the fold increase in
mRNA expression compared to wild type macrophages at time 0 was calculated by the comparative Ct method (2
2ddct). Data is presented as mean fold increase in
expression 6 S.E.M. Experiments were performed with n=4 in duplicate.
doi:10.1371/journal.pone.0039132.t003
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made in many other cell types, namely that the basal phosphor-
ylation of Ser910 and Ser935 is markedly reduced following
incubation with LRRK2 inhibitors. The finding that phosphor-
ylation of Ser910 and Ser935 induced by the MyD88 pathway is
not sensitive to LRRK2 inhibitors indicates that caution is needed
when using this assay to assess the efficacy of LRRK2 inhibitors in
cells that express TLR receptors, under conditions in which this
pathway may be activated. For example, if phosphorylation of
Ser910 and Ser935 is being used as a readout to assess efficacy of
LRRK2 inhibitors in vivo it is essential that conditions are used in
which the MyD88 pathway is not activated. It should be noted
that inhibitors of IKKs could not reduce the constitutive basal
phosphorylation of LRRK2.
In conclusion, we provide the first direct evidence that links the
IKKs with the LRRK2 kinase. Our results provide evidence that
the canonical as well as the non-canonical IKKs can phosphor-
ylate Ser935 and Ser910 and probably also Ser955, but only after
activation by the MyD88 pathway. This provides further evidence
that LRRK2 plays a role in macrophages, which will be important
to define in future, work. It will also be exciting to determine
whether defects in LRRK2 signalling in immune cells are linked to
the development of Parkinson’s disease in patients with LRRK2
mutations.
Table 4. mRNA expression in wild type and LRRK2 KO BMDM’s following PAM3CSK4 stimulation.
Gene Time =0 Time =4 h Time =8 h Time =12 h
WT KO WT KO WT KO WT KO
IL-6 1.060.24 1.160.09 32476838 33776548 2279165384 2040564896 2086665205 1709464900
IL-1b 1.060.28 1.060.13 7666182 7526113 26436336 24916139 19286292 15436255
TNFa 1.060.30 1.060.04 19.363.8 18.761.0 7.861.8 7.260.23 2.9760.69 2.5860.76
IFNb 1.060.35 1.360.43 15.563.7 19.064.3 26.866.9 25.964.3 9.962.9 9.661.5
IL-12(p70) 1.060.40 1.160.34 96625 94610 205647 19667 211655 168649
IL-12(p40) 1.060.30 1.160.43 16806428 15586131 30506876 25856215 29206814 20706428
Bone marrow derived macrophages from LRRK2 knockout mice and wild type littermate controls were plated at a density of 1610
6 in 2 ml of tissue culture media. Cells
were treated with 1 mg/ml Pam3CSK4 24 h after plating and RNA collected at the indicated time points. Gene expression was normalized to GAPDH and the fold
increase in mRNA expression compared to wild type macrophages at time 0 was calculated by the comparative Ct method (2
-ddct). Data is presented as mean fold
increase in expression 6 S.E.M. Experiments were performed with n=4 in duplicate.
doi:10.1371/journal.pone.0039132.t004
Figure 8. Acute IKK signalling is not impaired in LRRK2 knock-out macrophages. Bone marrow derived macrophages were prepared from
LRRK2 knock-out mice and littermate controls. BMDMs were treated with 100 ng/ml LPS for the indicated time points. Cells lysates were subjected to
immunoblot with the indicated antibodies. Results are representative of two independent experiments performed in duplicate.
doi:10.1371/journal.pone.0039132.g008
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Figure S1 TLR agonists increase LRRK2 phosphoryla-
tion at Serines 910 and 935 in RAW 264.7 cells. RAW
264.7 macrophages were treated with the following TLR agonists
for 1 h. 1 mg/ml Pam3CSK4, 10
8 cells HKLM, 10 mg/ml LMW
and HMW Poly(I:C), 100 ng/ml LPS, 10 mg/ml Flagellin, 1 mg/
ml FSL1, 1 mM CLO97 and 2.5 mM ODN1826. Lysates were
subjected to immunoblot with the indicated antibodies. Results are
representative of at least two independent experiments.
(TIF)
Figure S2 Effect of LRRK2-IN1 on LRRK2 phosphory-
lation in RAW cells. RAW 264.7 macrophages were pre-treated
with 1 mM LRRK2-IN1 or DMSO as control for 1 h then
stimulated plus or minus 100 ng/ml LPS for 1 h. Cell lysates were
prepared and subjected to immunoblot with the indicated
antibodies. Results are representative of at least two independent
experiments.
(TIF)
Method S1 Synthesis of NG25.
(DOC)
Table S1 ActivX selectivity profiling of NG25. Cellular
kinase selectivity as assessed using the KiNativ(tm) technology
[37]. Percent inhibition (color coded as indicated in the legend) of
kinase labeling by ATP-biotin that results from incubating HUH7
cells with the inhibitors at concentrations of 1 mM and 10 mMi s
indicated (larger numbers indicate stronger binding to the kinase).
(XLSX)
Table S2 Ambit selectivity profiling of NG25. Inhibitors
were screened at a single concentration of 10 mM. Scores are
related to the probability of a hit and are not strictly an affinity
measurement. At a screening concentration of 10 mM, a score of
less than 10% implies that the false positive probability is less than
20% and that the Kd value is most likely less than 1 mM. A score
between 1 and 10% implies that the false positive probability is less
than 10%, although it is difficult to assign a quantitative affinity
from a single-point primary screen. A score of less than 1% implies
that the false positive probability is less than 5% and that the Kd
value is most likely less than 1 mM.
(XLSX)
Table S3 International centre for kinase profiling of
NG25. The specificity of NG25 was examined against a panel of
over 100 kinases by the International Centre for Protein Kinase
Profiling, MRC Protein Phosphorylation Unit, University of
Dundee (www.kinase-screen.mrc.ac.uk) at concentrations of 0.1,
1 and 10 mM. The profiling of NG25 at 0.1 mM has been
published previously [36] however, we include it again for ease of
comparison with the other screening data. The results for each
protein kinase tested are expressed as percentage activity
remaining following inhibitor treatment compared to no inhibitor
controls.
(XLSX)
Table S4 qRT-PCR primers. Sense and anti-sense primer
sequences for the analysis of inflammatory gene expression by
qRT-PCR are listed.
(XLSX)
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